Evaluation of cellular, acellular, and matrix-like products in the management of nonhealing venous leg ulcers: an interim analysis of STABLECAMP
DOI:
https://doi.org/10.63676/s90cfx10Keywords:
interim analysis, venous leg ulcer, chronic wounds, tissue regeneration, Cellular, acellular, and matrix-like products , clinical trial designAbstract
Background: Venous leg ulcers (VLU), a painful and debilitating condition, adversely affect patient quality of life and impose a burden on health care systems across the globe. Existing standard of care (SOC) yields limited healing success, emphasizing the need for new and more effective treatment strategies.
Methods: An interim analysis of this multicenter, prospective, randomized controlled modified platform clinical trial evaluated the efficacy of cellular, acellular, and matrix-like products (CAMPs) with SOC versus SOC alone. The primary endpoint was percentage of target ulcers achieving complete wound closure in 12 weeks, defined as 100% reepithelialization without drainage for two consecutive weeks, confirmed by blinded independent review.
Results: In Intent-To-Treat (ITT), dual layer amniotic membrane allograft (DLAG) with SOC arm achieved a 50% closure rate versus 16.7% with SOC alone, an 33.3% absolute gain that was statistically significant (n=20, 95% CI 5.6% to 55.8%, p=0.018, α=0.05). All other treatment groups were not significant in the ITT population. All treatment groups were not significant in the Per Protocol (PP) population. Additionally, the percent area reduction (PAR) from TV-1 to TV-13 measured weekly with digital photographic planimetry, using an imaging device, and physical examination were analyzed. For ITT, DLAG + SOC outperformed SOC on both average and median wound-area reduction. For PP, DLAG + SOC outperformed SOC on both average and median wound-area reduction. Demographic summary statistics were analyzed to determine randomized baseline balance across groups, which was achieved with no statistically significant differences between groups at the time of interim analysis.
Conclusion: The interim analysis revealed that the placental membrane products trended to-wards superiority over SOC. The statistical significance in the ITT population for DLACG suggests that this product may be superior to SOC.
References
1. Carter MJ, DaVanzo J, Haught R, Nusgart M, Cartwright D, Fife CE. Chronic wound prevalence and the associated cost of treatment in Medicare beneficiaries: changes between 2014 and 2019. J Med Econ. 2023; 26(1):894-901. https://doi.org/10.1080/13696998.2023.2232256
2. Werdin, Frank et al. Evidence-based management strategies for treatment of chronic wounds. Eplasty. 2009; 9
3. Sierra-Juárez MA, Rejón-Cauich JE, Parada-Guzmán MG, Castañeda-Morales SA. Chronic venous disease: Literature re-view. Revista Médica Del Hospital General de México. 2021; 84(2)26 https://doi.org/10.24875/hgmx.20000072
4. Raffetto JD, Ligi D, Maniscalco R, Khalil RA, Mannello F. Why venous leg ulcers have difficulty healing: overview on patho-physiology, clinical consequences, and treatment. J Clin Med. 2020; 10(1)29. https://doi.org/10.3390/jcm10010029
5. Melikian R, O’Donnell TFO, Suarez L, Iafrati MD. Risk factors associated with the venous leg ulcer that fails to heal after 1 year of treatment. J Vasc Surg. Venous and lymphatic disorders. 2019; 7(1): 98-105. https://doi.org/10.1016/j.jvsv.2018.07.014
6. Harrisson MB, Graham ID, Friedberg E. Assessing the population with leg and foot ulcers. Can Nurse. 2001; 97: 2, 18–23
7. Abbade LPF, Lastoria S, Rollo HDA, Stolf HO. A sociodemographic, clinical study of patients with venous ulcer. Int J Der-matol. 2005; 44(12): 989-92. https://doi.org/10.1111/j.1365-4632.2004.02276.x
8. Ha JH, Jin H, Park J-U. Association between socioeconomic position and diabetic foot ulcer outcomes: a population-based cohort study in South Korea. BMC Public Health. 2021; 21(1) 1395. https://doi.org/10.1186/s12889-021-11406-3
9. Kolluri R, Lugli M, Beckman JA. An estimate of the economic burden of venous leg ulcers associated with deep venous dis-ease. Vascular medicine. 2022; 27(1): 63-72. https://doi.org/10.1177/1358863X211028298
10. Wu, Stephanie et al. Best practice for wound repair and regeneration use of cellular, acellular and matrix-like products (CAMPs). J Wound Care. 2023; 32(Sup4b): S1-S31. https://doi.org/10.12968/jowc.2023.32.Sup4b.S1
11. Serena TE, Tramelli B, King E, Maloumi S. A multicentre, prospective, randomized controlled modified platform trial evaluating purion processed lyophilized human amnion/chorion membrane and standard of care versus standard of care alone in the treatment of non-healing diabetic foot ulcers. 2025. Int J Tissue Repair; 1(1). https://doi.org/10.63676/ctkc9r79
Published
Data Availability Statement
The data is proprietary but is available on request to the corresponding author.
Issue
Section
License
Copyright (c) 2025 International Journal of Tissue Repair
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
